OnKure Therapeutics, Inc. (OKUR) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Boulder, CO, 美国. 现任CEO为 Nicholas A. Saccomano.
OKUR 拥有 IPO日期为 2021-04-08, 46 名全职员工, 在 NASDAQ Global Market, 市值为 $62.97M.
OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.
